Research and Markets, the largest resource for market research information in world providing essential market research reports, industry research, industry analysis, forecasts, market studies, company profiles and country reports.
Welcome - Register - Login - Help/FAQ - 0 items View Basket
Worlds Largest Market Research Resource - 712737 Live Reports
Search Research and Markets
  Search
Enter keywords, a title or
a report id number below.





Advanced   
Company search
Register for free email updates of market research
Currency
  Select a currency for use throughout the site



Viewing report

Order by Fax
Printer Friendly
PDF Brochure
EnterprisewideAdd to Basket
EnterprisewideAdd to Basket
Electronic (Online Access)Add to Basket
Hard CopyAdd to Basket
Electronic (PDF)Add to Basket
Live Chat Live Help Software for Website

The Pharmaceutical Market: Russia

Espicom Business Intelligence Ltd, Oct 2011, Pages: 66


  Description  
   Table of Contents   
   Companies Mentioned   
    
    
     
  Enquire before Buying   
  Send to a Friend   

THE PHARMACEUTICAL MARKET: RUSSIA - REVIEW

Russia accounts for two-fifths of the total Central & Eastern European pharmaceutical market, due to its large GDP and population of 142 million; however, in per capita terms, Russia is also one of the smallest markets, comparing to Romania. The Russian pharmaceutical market is predicted to expand at a relatively high CAGR in US dollar terms over the next few years and will continue to be driven by import growth; a heavy reliance on imports has resulted from the lack of locally-manufactured innovative pharmaceuticals. Over the last few years, import growth has been boosted by the federal drug supply system (DLO). Around 80% of DLO funds are spent on imported pharmaceuticals.

The government is currently implementing the Pharma 2020 Strategy, which aims to encourage growth in the local pharmaceutical industry for the period up to 2020. Under the plan, the government will help local producers to cover the costs of the R&D that is required to boost production of innovative pharmaceuticals. It also hopes to create new companies that will be able to attract investment, create new jobs and produce competitive, safe, good quality, affordable products that fulfil the requirements of patients and the healthcare system. If the objectives of the plan are realised, by 2020, the local industry will be responsible for 50% of drugs in circulation, 80% of which will be innovative. The Strategy will require a lot of investment which will be sourced mainly from the federal budget, but the government is also trying to encourage international pharmaceutical companies to invest. So far, companies such as AstraZeneca, Novo Nordisk and Nycomed have made plans to invest in Russia.

The presence of foreign manufacturers is increasing in Russia. A number of agreements have been made in 2011 between domestic and foreign companies which will benefit the Russian pharmaceutical market. These include a joint venture between India's Aurobindo Pharma and Russia's OJSC Diod; a licensing agreement between Norgine and Nycomed that gives the latter exclusive rights to commercialise MoviPrep in Russia; investment by Rusnano, Russia’s government investment company, in Cleveland BioLabs' new subsidiary, Panacela Labs, which will develop a portfolio of new preclinical drug candidates in Russia; Pfizer and ChemRar High Technology Centre signing a memorandum of understanding to explore a collaboration focused on the research, development and commercialisation of innovative drugs in Russia; and the launching of Pro Bono Bio as a new international pharmaceutical company as a result of a three-year Anglo/Russian project.

ENHANCED STRATEGIC INTELLIGENCE

These highly regarded world pharmaceutical market reports have been redesigned to provide enhanced strategic intelligence in a user-friendly format. Each report provides in-depth information, setting the pharmaceutical market in context. The reports provide:

- Five-year projections for economic, demographic, health expenditure, health workforce and pharmaceutical market indicators.
- Specialised intelligence on OTCs, generics, biologics and biosimilars.
- Exclusive economic and demographic data from the Economist Intelligence Unit (EIU) for each market in the series.
- A separate statistical health file, comprising health expenditure, health infrastructure, health services and health personnel.
- The reports are updated quarterly, providing you with the latest information for a full year. In addition, the service will keep you up to date with market and industry news on a regular basis.

HEALTHCARE STATISTICS

A comprehensive tabula review, comprising demographics, epidemiology, health expenditure, hospital and primary care infrastructure & services and healthcare personnel, is additionally included.



Customers who bought this item also bought

The Pharmaceutical Market: Pakistan

The Pharmaceutical Market: Turkey

The Pharmaceutical Market: Austria

The Pharmaceutical Market: Singapore

The Pharmaceutical Market: Vietnam

The Pharmaceutical Market: Canada

The Pharmaceutical Market: Ukraine

The Pharmaceutical Market: Germany

The Pharmaceutical Market: Malaysia

The Pharmaceutical Market: Estonia



For enquiries please call us on:
  +353-1-415-1241 (GMT Office Hours)
  1-800-526-8630 (US/Canada Toll Free)
  1-917-300-0470 (EST Office Hours)

   All rights reserved. © Copyright 2012 Research and Markets
   Terms and conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network


Research and Markets RSS Feeds